AbolerIS Pharma

French tech company | Builders Republic

About

Clinical-stage biotech developing an anti-CD45RC monoclonal antibody (ABO21009) that selectively depletes pathogenic T and B cells while preserving regulatory immunity — targeting rheumatoid arthritis, inflammatory bowel disease, Sjögren's disease, and organ transplant rejection.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Seed
Founded
2018
City
NANTES
Region
Pays de la Loire
Tracked rounds
1
Amount raised
2.5 M€ raised since 2020

Funding rounds

  • Seed — 2020

Investors